Abbott Laboratories (NYSE:ABT) Expected to Announce Earnings of $1.11 Per Share

Analysts expect that Abbott Laboratories (NYSE:ABTGet Rating) will announce earnings per share (EPS) of $1.11 for the current quarter, Zacks reports. Six analysts have provided estimates for Abbott Laboratories’ earnings, with the highest EPS estimate coming in at $1.33 and the lowest estimate coming in at $1.01. Abbott Laboratories reported earnings per share of $1.17 in the same quarter last year, which would indicate a negative year over year growth rate of 5.1%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Abbott Laboratories will report full-year earnings of $4.82 per share for the current financial year, with EPS estimates ranging from $4.70 to $5.21. For the next fiscal year, analysts forecast that the firm will report earnings of $4.88 per share, with EPS estimates ranging from $4.49 to $5.63. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Abbott Laboratories.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its quarterly earnings data on Wednesday, April 20th. The healthcare product maker reported $1.73 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.26. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The company had revenue of $11.90 billion during the quarter, compared to analysts’ expectations of $11 billion. During the same period in the prior year, the business earned $1.32 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.8% compared to the same quarter last year.

Several equities research analysts recently weighed in on ABT shares. Raymond James reduced their target price on shares of Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Credit Suisse Group lifted their price objective on Abbott Laboratories from $138.00 to $139.00 and gave the stock an “outperform” rating in a report on Thursday, January 27th. Morgan Stanley cut their target price on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, January 27th. UBS Group lifted their price target on shares of Abbott Laboratories from $138.00 to $142.00 and gave the stock a “buy” rating in a research note on Thursday, January 27th. Finally, StockNews.com initiated coverage on shares of Abbott Laboratories in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $138.83.

In other news, EVP Mary K. Moreland sold 400 shares of the firm’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $119.31, for a total transaction of $47,724.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $113.22, for a total transaction of $5,661,000.00. Following the completion of the sale, the director now directly owns 6,973,500 shares of the company’s stock, valued at approximately $789,539,670. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,896 shares of company stock valued at $9,299,454. Company insiders own 0.52% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. SVB Wealth LLC increased its holdings in shares of Abbott Laboratories by 3.8% in the first quarter. SVB Wealth LLC now owns 513,661 shares of the healthcare product maker’s stock valued at $60,798,000 after purchasing an additional 18,635 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Abbott Laboratories by 12.3% in the first quarter. Proficio Capital Partners LLC now owns 8,077 shares of the healthcare product maker’s stock valued at $956,000 after purchasing an additional 887 shares in the last quarter. Centaurus Financial Inc. increased its holdings in shares of Abbott Laboratories by 6.5% in the first quarter. Centaurus Financial Inc. now owns 7,323 shares of the healthcare product maker’s stock valued at $867,000 after purchasing an additional 445 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Abbott Laboratories by 3.9% in the first quarter. Ameritas Investment Partners Inc. now owns 64,941 shares of the healthcare product maker’s stock valued at $7,686,000 after purchasing an additional 2,445 shares in the last quarter. Finally, Fort Point Capital Partners LLC boosted its stake in Abbott Laboratories by 19.3% in the first quarter. Fort Point Capital Partners LLC now owns 6,177 shares of the healthcare product maker’s stock valued at $731,000 after acquiring an additional 1,000 shares during the last quarter. 73.46% of the stock is owned by institutional investors and hedge funds.

NYSE ABT traded up $1.91 during midday trading on Monday, hitting $109.88. The company had a trading volume of 6,159,308 shares, compared to its average volume of 5,167,185. The firm has a fifty day simple moving average of $117.37 and a two-hundred day simple moving average of $124.75. Abbott Laboratories has a fifty-two week low of $104.63 and a fifty-two week high of $142.60. The company has a quick ratio of 1.40, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. The stock has a market cap of $192.39 billion, a price-to-earnings ratio of 25.49, a P/E/G ratio of 2.81 and a beta of 0.73.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 16th. Investors of record on Friday, April 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.71%. The ex-dividend date is Wednesday, April 13th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 43.62%.

Abbott Laboratories Company Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.